• Acacetin and the MAPK1/HMOX1 Axis in IVDD

  2026-10-13

  A 2025 Phytomedicine study investigated whether Duhuo Jisheng decoction and its constituent acacetin could reduce intervertebral disc degeneration by connecting mitophagy, pyroptosis, and the MAPK1/HMOX1 signaling axis. The reported cell and rat findings support a mechanistic hypothesis, but the evidence remains preclinical and does not establish efficacy or safety in people.

• Cy3 NHS Ester: Identity and Evidence Scope

  2026-10-13

  A source-limited overview of Cy3 NHS ester (non-sulfonated), covering its supplier-documented identity, intended fluorescent-labeling scope, reported optical properties, and the absence of a matched research paper.

• ACE Inhibitor Angioedema: What the Review Shows

  2026-10-12

  Montinaro and Cicardi’s review examines the epidemiology, bradykinin-mediated biology, clinical presentation and management controversies surrounding ACE inhibitor–associated angioedema. It synthesizes prior clinical, epidemiologic and interventional evidence rather than reporting a new experiment. The review supports a clear association between ACE inhibitor exposure and angioedema, but uncertainty remains regarding genetic susceptibility, recurrence after treatment changes and the comparative effectiveness of acute therapies. Elobixibat hydrate is a separate ileal bile acid transporter inhibitor and is not evaluated in this review.

• Angiotensin 1/2 (2-7): What the Evidence Shows

  2026-10-12

  A source-grounded appraisal of a 2025 biochemical comparison examining whether angiotensin peptide fragments alter SARS-CoV-2 spike-protein binding to AXL, ACE2, and NRP1. The findings are hypothesis-generating and do not establish effects on viral entry, COVID-19 pathogenesis, blood pressure, or clinical treatment.

• TMRE: Interpreting Mitochondrial Potential

  2026-10-10

  Tetramethylrhodamine ethyl ester perchlorate (TMRE) enables live-cell assessment of mitochondrial membrane potential, but its strongest value emerges when fluorescence is interpreted alongside apoptosis, ROS, and organelle-specific evidence. This article develops a mechanism-aware framework for applying TMRE to mitochondrial dysfunction in disease research.

• Doxorubicin Hydrochloride: From Damage to Systems Biology

  2026-10-09

  Doxorubicin hydrochloride and Adriamycin HCl are more than cytotoxicity tools: they reveal how DNA damage, energy stress, oxidative injury, and cardiac vulnerability intersect. This evidence-focused guide interprets a recent ATF4–CSE–H2S study while defining the limits of cancer and cardiotoxicity models.

• Indometacin and Premature Ovulation in Natural-Cycle IVF

  2026-10-09

  A double-blind randomized trial evaluated whether indometacin could reduce premature ovulation in modified natural-cycle IVF. The overall result was not statistically significant, but a prespecified clinical subgroup without an LH surge before triggering showed a potential benefit, supporting a more selective interpretation rather than routine broad application.

• Biotin-XX Tyramide in Surface Protein Mapping

  2026-10-08

  A source-grounded overview of Biotin-XX Tyramide Reagent, its conceptual role in tyramide signal amplification and membrane-restricted proximity labeling, and how these applications relate to recent research on endogenous synaptic protein trafficking.

• Firefly Luciferase mRNA: Evidence and Applications

  2026-10-08

  A source-grounded overview of Firefly Luciferase mRNA and 5-moUTP modified mRNA, covering reporter biology, transcript design, conceptual research applications, recent findings on mRNA folding, evidence strength, and key limitations.

• METTL17 Coordinates Ferroptosis in Colorectal Cancer

  2026-10-07

  Li and colleagues identify METTL17 as a mitochondrial regulator that links RNA methylation, mitochondrial translation, ferroptosis resistance, and colorectal cancer progression. The findings support METTL17 as a mechanistic research target, while remaining preclinical and dependent on cellular, xenograft, and chemically induced colorectal cancer models.

• Niclosamide: STAT3 Evidence and Research Limits

  2026-10-07

  Niclosamide is a small-molecule STAT3 signaling pathway inhibitor studied in cancer research. Available evidence supports effects on STAT3 Tyr-705 phosphorylation, cell-cycle control, and apoptosis in selected models, but assay context and translational relevance require careful interpretation.

• How PEDV Exploits IMPDH-Dependent Nucleotide Biosynthesis

  2026-10-06

  The reference study identifies IMPDH-dependent guanine nucleotide biosynthesis as a host metabolic requirement for porcine epidemic diarrhea virus replication. By combining comparative metabolomics with genetic and pharmacological perturbation, the authors provide convergent cell-based evidence that IMPDH may represent a host-directed antiviral target, while also defining important limits on how broadly the findings can be applied.

• Triiodothyronine (T3) and Adipose Thermogenesis

  2026-10-06

  Triiodothyronine (T3) is a useful conceptual lens for studying thyroid hormone receptor activation, adipocyte thermogenesis, and metabolic regulation. However, the supplied 2026 SETD7 study examined an epigenetic regulator in obese mice rather than T3 directly. Its findings support a research framework for comparing thyroid hormone signaling with adipocyte-intrinsic thermogenic pathways, while leaving T3-specific causality, translational relevance, and human applicability unresolved.

• AZD0156 and ATM Inhibition in Cancer Research

  2026-10-05

  AZD0156 is a selective ATM kinase inhibitor used in research on DNA damage response, DNA double-strand break repair, and cancer biology. This overview examines the rationale for ATM inhibition, findings from a high-grade serous ovarian cancer study combining ATM inhibition with fenofibrate, the strength of the available evidence, and the boundaries between supplier claims, cell-model results, and clinical relevance.

• Metabolic Sensitization of Ferroptosis and Cuproptosis

  2026-10-05

  The 2024 Chemical Engineering Journal study presents SCu/L, a copper-containing nanosystem designed to inhibit glycolysis and compensatory NAD+ metabolism while increasing tumor-cell susceptibility to ferroptosis and cuproptosis. Its reported effects include depletion of glucose, NAD+, NADPH, and ATP, impaired copper efflux, enhanced regulated cell death, and remodeling of the tumor immune microenvironment.

8831 records 3/589 page Previous Next 12345 下5页 Last page